1. Home
  2. TTGT vs NGEN Comparison

TTGT vs NGEN Comparison

Compare TTGT & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TechTarget Inc.

TTGT

TechTarget Inc.

HOLD

Current Price

$4.47

Market Cap

245.8M

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$1.61

Market Cap

197.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TTGT
NGEN
Founded
1999
2017
Country
United States
Canada
Employees
N/A
9
Industry
Telecommunications Equipment
Sector
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
245.8M
197.5M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
TTGT
NGEN
Price
$4.47
$1.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$10.75
$18.00
AVG Volume (30 Days)
349.8K
692.6K
Earning Date
05-07-2026
04-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.45
N/A
Revenue Next Year
$2.75
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.37
$1.58
52 Week High
$7.37
$5.93

Technical Indicators

Market Signals
Indicator
TTGT
NGEN
Relative Strength Index (RSI) 60.80 32.57
Support Level $3.52 $1.59
Resistance Level $4.75 $2.22
Average True Range (ATR) 0.33 0.10
MACD 0.11 0.01
Stochastic Oscillator 83.27 2.67

Price Performance

Historical Comparison
TTGT
NGEN

About TTGT TechTarget Inc.

TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. The company provides marketing and sales services that deliver business impact for enterprise technology companies. It develops editorial content across multiple technology-focused websites and channels to engage audiences researching information technology solutions. The company generates revenue by providing market insight and market access to the technology market, including enterprise technology, artificial intelligence, channel, cybersecurity, media & entertainment, and service providers. Geographically, it derives the majority of revenue from North America.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: